Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab Plus Nivolumab in Pediatric and Young Adult R/R cHL and NHL
NCT05255601Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 7
01
Overview
A Phase 2 trial of relatlimab in Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NHL), sponsored by Bristol Myers Squibb. Started Sep 2022; status: terminated.
02
Drugs
relatlimab
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05255601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05255601.